Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-006622
Filing Date
2020-05-14
Accepted
2020-05-14 17:00:04
Documents
99
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q zcor-20200331x10q.htm 10-Q 3273559
2 EX-31.1 zcor-20200331ex311b3587f.htm EX-31.1 17330
3 EX-32.1 zcor-20200331ex321c788ac.htm EX-32.1 8886
  Complete submission text file 0001558370-20-006622.txt   14018973

Data Files

Seq Description Document Type Size
4 EX-101.INS zcor-20200331.xml EX-101.INS 3583053
5 EX-101.SCH zcor-20200331.xsd EX-101.SCH 92306
6 EX-101.CAL zcor-20200331_cal.xml EX-101.CAL 89432
7 EX-101.DEF zcor-20200331_def.xml EX-101.DEF 349691
8 EX-101.LAB zcor-20200331_lab.xml EX-101.LAB 705707
9 EX-101.PRE zcor-20200331_pre.xml EX-101.PRE 603888
Mailing Address 600 LEE ROAD SUITE 100 WAYNE PA 19087
Business Address 600 LEE ROAD SUITE 100 WAYNE PA 19087 610-833-4200
Zyla Life Sciences (Filer) CIK: 0001586105 (see all company filings)

EIN.: 463575334 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36295 | Film No.: 20878684
SIC: 2834 Pharmaceutical Preparations